The Trade Related Aspects of Intellectual Property Rights (TRIPS) - Pharmaceuticals Transitional Period: Can it Help Build Capacity in African Least Developed Countries (LDCs)?

Abstract

ABSTRACTAfrican least developed countries LDCs face unique challenges in the implementation of minimum standards for the protection of IPRs, most poignantly illustrated in the field of pharmaceuticals. This was to an extent recognised by the World Trade Organization (WTO) in providing a transitional period during which LDCs are not obliged to implement the Trade Related Aspects of Intellectual Property Rights (TRIPS) Agreement in order to afford them an opportunity to develop a viable technological base in the pharmaceutical sector before being required to provide patent protection for pharmaceuticals. This article explores some options available to African least developed countries LDCs to use the transitional period in a manner that could help develop their pharmaceutical manufacturing capacity. Rwanda has already shown itself to be a pioneer in the use of policy flexibility available in the TRIPS Agreement and related instruments to fulfil the country's demand for essential pharmaceutical products. Therefore, much of the analysis draws on Rwanda for illustrative purposes.